Biomay Ag

Birgit Linhart

Rudolf Valenta

Peter Valent

Dietrich Kraft

Margarete Focke-Tejkl

Susanne Vrtala

Susanne Spitzauer

Ines Swoboda

Katharina Blatt

Hans Grönlund

Kerstin Westritschnig

Marianne Van Hage

Theresia Popow-Kraupp

Sabine Stumvoll

Maria-Theresa Krauth

Margit Focke

Nadine Mothes

Angela Neubauer

Anna Gieras

Raffaela Campana

Johanna Tinhofer

Renate Reininger

The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.

Vaccine carrier

The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.

Hypoallergenic hybrid polypeptides for the treatment of allergy

Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.

Hypallergenic mosaic antigens and methods of making same

Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.

Allergy vaccines containing hybrid polypeptides

A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.

Process for the preparation of hypoallergenic mosaic antigens

Growing community of inventors

Weissenkirchen, Austria

Birgit Linhart